Virax Biolabs Group Limited Ordinary Shares (VRAX) stock price

Virax Biolabs Group Limited Ordinary Shares (VRAX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.54 (+0.40%), Market cap $0.00B, 52-week low–high $0.10 ~ $1.11.

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, pro

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Virax Biolabs Group Limited Ordinary Shares are updated in real time on BlackAll Trade.

Virax Biolabs Group Limited Ordinary Shares financial summary

Analyst outlook

Key ratios · profitability · growth

Frequently asked questions

What is the current Virax Biolabs Group Limited Ordinary Shares (VRAX) stock price?

Virax Biolabs Group Limited Ordinary Shares trades at $2.54 (+0.40%). Real-time quotes and charts are available on BlackAll Trade.

What is the Virax Biolabs Group Limited Ordinary Shares (VRAX) market cap?

Virax Biolabs Group Limited Ordinary Shares has a market cap of about $0.00B.

What does Virax Biolabs Group Limited Ordinary Shares (VRAX) do?

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro